ERBB2 and breast carcinoma: Nakamura et al. reported that, in HER2-positive primary breast cancer, the rate of HER2 loss in the site of recurrence was significantly higher in patients treated with trastuzumab than in patients treated without trastuzumab (37% versus 6%) [11].